Search

Your search keyword '"Barta, Stefan"' showing total 188 results

Search Constraints

Start Over You searched for: Author "Barta, Stefan" Remove constraint Author: "Barta, Stefan" Database ScienceDirect Remove constraint Database: ScienceDirect
188 results on '"Barta, Stefan"'

Search Results

4. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study

5. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation

6. ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome

7. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas

8. Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy

9. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines

12. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma

14. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort

15. Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study

17. Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells

18. Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial

19. Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL

20. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

22. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma

24. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

27. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

29. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

35. Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy

38. Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome

40. Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study

41. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

42. Postibrutinib relapse outcomes for patients with marginal zone lymphoma

43. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients

46. TCL-394 Valemetostat for Patients With R/R Peripheral T-Cell Lymphomas (PTCLs): A Phase 2 VALENTINE-PTCL01 Trial

47. Valemetostat for Patients With R/R Peripheral T-Cell Lymphomas (PTCLs): A Phase 2 VALENTINE-PTCL01 Trial

50. Valemetostat for Patients With R/R Peripheral T-Cell Lymphomas (PTCLs): A Phase 2 VALENTINE-PTCL01 Trial

Catalog

Books, media, physical & digital resources